MATRIX Penny Stocks

[pivotpoint1]

ARTH ~ Overview

Bleeding and leakage remain compelling problems to solve. Patients matter.

The AC5 Surgical Hemostatic Device™ value proposition is based on the premise of faster and safer surgery. The product is designed to be simple (user-friendly), effective (works promptly), versatile (useful in challenging situations such as laparoscopic surgery**), and safe. These claims alongside the multipurpose nature of AC5™ distinguish it from first-generation solutions currently in use.

Large markets filled with problem products

In 2012, annual worldwide sales were over $2.8B for hemostatic agents and nearly $1.3B for fibrin and other sealants, which seal other leaks (cerebrospinal fluid, pleural, etc.). These products are anticipated to surpass global combined sales of over $7B in 2017.

http://www.archtherapeutics.com/market/overview